Sangamo Therapeutics (SGMO)
(Delayed Data from NSDQ)
$0.46 USD
-0.03 (-5.33%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $0.45 -0.01 (-1.51%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SGMO 0.46 -0.03(-5.33%)
Will SGMO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SGMO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SGMO
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates
SGMO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates
Novavax (NVAX) Beats Q1 Earnings and Revenue Estimates
Regenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Other News for SGMO
Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call Transcript
Sangamo Therapeutics Inc (SGMO) Q2 2025 Earnings Call Highlights: Promising Fabry Disease ...
Q2 2025 Sangamo Therapeutics Inc Earnings Call Transcript
Sangamo Therapeutics, Inc. 2025 Q2 - Results - Earnings Call Presentation
Sangamo Therapeutics GAAP EPS of -$0.08 misses by $0.04, revenue of $18.3M misses by $13.38M